コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 permeability that are characteristic of non-proliferative diabetic retinopathy.
2 sive neovascularization in the retina causes proliferative diabetic retinopathy.
3 lly relevant to the angiogenesis observed in proliferative diabetic retinopathy.
4 ization of ischemic retinal diseases such as proliferative diabetic retinopathy.
5 ACCORD trial participants with no history of proliferative diabetic retinopathy.
6 agents also provide therapeutic benefits in proliferative diabetic retinopathy.
7 ents broadens therapeutic options for PRP in proliferative diabetic retinopathy.
8 eatment for reducing severe visual loss from proliferative diabetic retinopathy.
9 at least through 2 years, for patients with proliferative diabetic retinopathy.
10 rence of neovascularization in patients with proliferative diabetic retinopathy.
11 sis that occurs in blinding diseases such as proliferative diabetic retinopathy.
12 nd that this change can precede the onset of proliferative diabetic retinopathy.
13 se with moderately severe to very severe non proliferative diabetic retinopathy.
14 eased in the vitreous fluid of patients with proliferative diabetic retinopathy.
15 safety of combined surgery in patients with proliferative diabetic retinopathy.
16 dergone cataract surgery (39.9%), those with proliferative diabetic retinopathy (25.7%), and those wi
17 ferative diabetic retinopathy (NPDR), 15 had proliferative diabetic retinopathy, 7 had retinal detach
18 cluding 0.9% of all injections that were for proliferative diabetic retinopathy), 8.3% to treat retin
19 and other pathological conditions, including proliferative diabetic retinopathy and age-related macul
20 ion and ocular permeability are hallmarks of proliferative diabetic retinopathy and age-related macul
21 thology related to both nonproliferative and proliferative diabetic retinopathy and age-related macul
22 meability contributes to the pathogenesis of proliferative diabetic retinopathy and diabetic macular
23 including age-related macular degeneration, proliferative diabetic retinopathy and glaucomatous opti
24 udies related to retinopathy of prematurity, proliferative diabetic retinopathy and in studies evalua
25 ear, however, how PlGF, which is elevated in proliferative diabetic retinopathy and is a VEGF homolog
27 serum lipids or statins on the incidence of proliferative diabetic retinopathy and macular edema.
29 and is an excellent target for treatment of proliferative diabetic retinopathy and other ischemic re
30 angiogenesis and vascular remodeling during proliferative diabetic retinopathy and other ischemic re
31 n the retina that underlies the pathology of proliferative diabetic retinopathy and retinopathy of pr
32 numerous angiogenesis-based diseases such as proliferative diabetic retinopathy and solid tumors.
33 d in the serum and vitreous of patients with proliferative diabetic retinopathy and that smooth muscl
34 actor (IGF) biological activity increases in proliferative diabetic retinopathy and that this activit
35 d with a variety of human diseases including proliferative diabetic retinopathy and wet age-related m
36 idated scale from stage 0 (none) to stage 4 (proliferative diabetic retinopathy), and percentage of t
37 vitreous of patients with complications from proliferative diabetic retinopathy, and correlate with I
38 sening of diabetic retinopathy, incidence of proliferative diabetic retinopathy, and incidence of mac
39 ty factor is a likely angiogenic mediator in proliferative diabetic retinopathy, and its role is unde
40 nti-VEGF drugs in DME is not as robust as in proliferative diabetic retinopathy, and many patients wi
42 went vitrectomy for complications related to proliferative diabetic retinopathy, and the other 13 for
43 diseases such as retinopathy of prematurity, proliferative diabetic retinopathy, and wet age-related
44 4 patients undergoing primary vitrectomy for proliferative diabetic retinopathy at 16 different vitre
45 (DME) at baseline, were less likely to have proliferative diabetic retinopathy at baseline, received
46 ks and benefits of pars plana vitrectomy for proliferative diabetic retinopathy, but clinical trial d
47 generating tractional forces associated with proliferative diabetic retinopathy can arise from Muller
48 r progression of retinopathy, progression to proliferative diabetic retinopathy, clinically significa
49 nducted at 55 US sites among 305 adults with proliferative diabetic retinopathy enrolled between Febr
50 range of prevalent ocular diseases including proliferative diabetic retinopathy, exudative age-relate
51 risk of severe vision loss in patients with proliferative diabetic retinopathy for the past four dec
53 separate studies reported that patients with proliferative diabetic retinopathy have increased serum
54 period was associated with the incidence of proliferative diabetic retinopathy (hazard ratio [HR], 1
57 athy as defined by diabetic macular edema or proliferative diabetic retinopathy in unrelated cases as
58 , anecdotal evidence has long suggested that proliferative diabetic retinopathy is rarely associated
60 zed broadly as proliferation, exemplified by proliferative diabetic retinopathy, leakage such as macu
65 tein cholesterol and decreased prevalence of proliferative diabetic retinopathy (odds ratio per 10 mg
66 y [NPDR]; 22 moderate NPDR; 9 severe NPDR; 5 proliferative diabetic retinopathy) of 40 diabetic patie
67 Overall, the probability of progression to proliferative diabetic retinopathy or clinically signifi
68 e risk of progression from no retinopathy to proliferative diabetic retinopathy or clinically signifi
69 o determine the likelihood of progression to proliferative diabetic retinopathy or clinically signifi
70 defined by prior laser treatment for either proliferative diabetic retinopathy or diabetic macular e
71 density lipoprotein cholesterol and incident proliferative diabetic retinopathy or macular edema, nor
72 or of statin use with decreased incidence of proliferative diabetic retinopathy or macular edema, wer
73 ns were especially elevated in patients with proliferative diabetic retinopathy or retinal detachment
74 presumed ocular histoplasmosis syndrome (6), proliferative diabetic retinopathy (PDR) (5), epiretinal
75 5 individuals with type 1 or 2 diabetes with proliferative diabetic retinopathy (PDR) and 61 individu
76 e diagnosis of diabetes to sight-threatening proliferative diabetic retinopathy (PDR) and diabetic ma
77 nolone acetonide (FAc) on the progression to proliferative diabetic retinopathy (PDR) and the impact
78 ine the time and risk factors for developing proliferative diabetic retinopathy (PDR) and vitreous he
79 Age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR) are one of the
81 iabetic retinopathy (NPDR) was found in 69%, proliferative diabetic retinopathy (PDR) in 31% and adva
82 ctors for events that represent worsening of proliferative diabetic retinopathy (PDR) in eyes treated
86 alogues have been successfully used to treat proliferative diabetic retinopathy (PDR) that is unrespo
89 show that vitreal fluids from patients with proliferative diabetic retinopathy (PDR) were enriched w
90 death, eyes with macular hole, and eyes with proliferative diabetic retinopathy (PDR) were investigat
91 hy (NPDR) without macular edema, 20 eyes had proliferative diabetic retinopathy (PDR) without macular
92 c ischemic optic neuropathy (NAION), treated proliferative diabetic retinopathy (PDR), and branch ret
93 moderate to severe retinopathy, and 28 with proliferative diabetic retinopathy (PDR), previously tre
95 ers have been developed for the treatment of proliferative diabetic retinopathy (PDR), the leading ca
96 pars plana vitrectomy, while in a case with proliferative diabetic retinopathy (PDR), vitrectomy was
97 retinal photocoagulation (PRP) when managing proliferative diabetic retinopathy (PDR), with or withou
109 ignificantly lower in diabetic patients with proliferative diabetic retinopathy (PDR; respectively, 2
110 ages of DR (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]) have a higher
113 atin (SST) analogues have been used to treat proliferative diabetic retinopathy, pseudotumor cerebri,
114 ommon in eyes with retinal diseases, such as proliferative diabetic retinopathy, retinal vein occlusi
116 n patients with severe NPDR or non-high-risk proliferative diabetic retinopathy, the same association
118 ompared with diabetes alone, the presence of proliferative diabetic retinopathy was associated with a
120 branes surgically removed from patients with proliferative diabetic retinopathy were analyzed by zymo
121 ously untreated or post-laser treated active proliferative diabetic retinopathy were recruited from 2
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。